This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
E-Cigarette Users Have Lower Exposure to ... Dual cigarette/e-cigarette users may be exposed to even higher ... (16 Dec 2018)
Duration of Infertility in Men May Affect ... A longer duration of infertility was associated with lower sperm ... (13 Dec 2018)
Cannabis-Based Compound May Reduce Seizures ... Interest has been growing in the use of cannabinoids—the active ... (13 Dec 2018)
Study Reveals Sleep Problems in Young Adult ... A study published in the Journal of Sleep Research indicates ... (13 Dec 2018)
Risk Factors for Falling Are Different in ... Different factors were associated with falling in men versus ... (10 Dec 2018)
Monday, 14 May 2018 20:18

Osteoporosis Drug May Benefit Heart Health Featured

Rate this item
(0 votes)

The osteoporosis drug alendronate was linked with a reduced risk of cardiovascular death, heart attack, and stroke in a Journal of Bone and Mineral Research study of patients with hip fractures. The association was seen for up to 10 years after fracture.

In the study, patients newly diagnosed with hip fracture from 2005 through 2013 were followed until late 2016. Among 34,991 patients, 4602 (13%) received osteoporosis treatment during follow-up.

Alendronate was associated with 67% and 45% lower risks of one-year cardiovascular death and heart attack, respectively. It was associated with an 18% reduced risk of stroke within five years and a 17% reduced risk of stroke within 10 years. Protective effects were not evident for other classes of osteoporosis treatments.

“It is well established that there is a world-wide crisis in the treatment of osteoporosis, due to patients’ awareness of the extremely rare side effects,” said senior author Dr. Ching-Lung Cheung, of the University of Hong Kong. “Our findings show that alendronate is potentially cardioprotective in hip fracture patients. Therefore, physicians should consider prescribing alendronate or other nitrogen-containing bisphosphonates to hip fracture patients soon after their fracture, and patients should also have good compliance with alendronate treatment, as this is not only good for your bones, but also your heart.”

In addition to clinical management, the study also has important implications in clinical trial design of anti-osteoporosis medications. The US Food and Drug Administration recently requested more data before reaching a decision on whether to approve the osteoporosis drug romosozumab, due to excess cardiovascular adverse events in the romosozumab arm compared with the alendronate arm. “In light of these important deliberations, our results suggest that such differences in cardiovascular adverse events could be potentially related to a protective association of alendronate, rather than an increase in cardiovascular adverse events related to romosozumab use, said Dr. Cheung.”


Source: Wiley
Full bibliographic information

Chor-Wing Sing, Angel YS Wong, Douglas P Kiel, Elaine YN Cheung, Joanne KY Lam, Tommy T Cheung, Esther W Chan, Annie WC Kung, Ian CK Wong and Ching-Lung Cheung. Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture. Journal of Bone and Mineral Research. DOI: 10.1002/jbmr.3448. 

Read 407 times Last modified on Tuesday, 15 May 2018 18:30

Latest news

Highlights

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…